This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A single ulcer caused by L. tropica or L. major which is not likely to be contaminated by bacteria and is cosmetically acceptable may be left to heal spontanesouly. In all other circumstances cutaneous leishmaniasis, especially diffuse and mucocutaneous disease, should be treated.

The first line drug in the treatment of leishmaniasis is the pentavalent antimony compound, sodium stibogluconate. Treatment is inconvenient because the drug must be given by daily intravenous injection for 20-30 days.

For resistant disease pentamidine or liposomal amphoteracin may be used.


  • there is evidence from a small study showing the effectiveness of topically applied granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to antimonial therapy in the management of cutaneous leishmaniasis


  1. Santos JB et al. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 2004;190:1793-6.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.